This reinforced the need for a comprehensive understanding of the implications of GSG2 in thyroid cancer progression and opens avenues for potential therapeutic interventions targeting GSG2-mediated drug resistance. This evidence concerns the gene HASPIN and thyroid gland carcinoma.